| Description | The MAN-1 antibody has demonstrated an ability to bind to immobilized Mac-1 l-domain peptide (KFGDPLGYEDVIPEADR). It is important to note that MAN-1 has been found to exhibit cross-reactivity with β2-integrins other than Mac-1. Furthermore, MAN-1 has been shown to effectively inhibit the binding of activated monocytes to immobilized human endothelial cells under shear flow conditions. MAN-1 inhibits ICAM-1 binding to activated Mac-1. |
| Clonality | Monoclonal |
| Host Species | Mouse |
| Target Species | Human |
| Immunogen | Mac-1 l-domain peptide (KFGDPLGYEDVIPEADR) as the immunogen. |
| Epitope | l-domain-region Lys245-Arg261, KFGDPLGYEDVIPEADR |
| Isotype | Mouse IgG |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated, also available for Biotin, HRP, FITC and PE-labeled form. |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Purified with Protein A or G affinity chromatography |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | FC; ELISA; Inhib; IP |
| Application Notes | Inhibit: 10 μg/mL IP: 10 μg/mL |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | ITGAM |
| Alternative Name | CR3A; MO1A; CD11B; MAC-1; MAC1A; SLEB6 |
| Gene ID | 3684 |
| UniProt | P11215 |
| Related pathway | Autophagy |
| Research Area | Autophagy |
| Related Disease | Crohn's disease, colitis ulcerosa, multiple sclerosis, sarcoidosis, psoriasis, atherosclerosis and its clinical sequelae, scleroderma, intestinal adhesions, hypertrophic scars, rheumatoid arthritis, septicemia, autoimmune disease, acute coronary syndrome, HIV infection, and ischemia and reperfusion injuries, neointimal thickening, infiltration of polymorpholeucocytes, autoimmune disease, and neovascularisation-mediated diseases. |
